WO2012046730A1 - ヘルパーt細胞の活性化方法 - Google Patents
ヘルパーt細胞の活性化方法 Download PDFInfo
- Publication number
- WO2012046730A1 WO2012046730A1 PCT/JP2011/072874 JP2011072874W WO2012046730A1 WO 2012046730 A1 WO2012046730 A1 WO 2012046730A1 JP 2011072874 W JP2011072874 W JP 2011072874W WO 2012046730 A1 WO2012046730 A1 WO 2012046730A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hla
- molecule
- drb1
- peptide
- dpb1
- Prior art date
Links
- 210000002443 helper t lymphocyte Anatomy 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 79
- 230000003213 activating effect Effects 0.000 title claims abstract description 29
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 claims abstract description 386
- 108010039343 HLA-DRB1 Chains Proteins 0.000 claims abstract description 386
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 225
- 108700020467 WT1 Proteins 0.000 claims abstract description 160
- 101150084041 WT1 gene Proteins 0.000 claims abstract description 160
- 102000040856 WT1 Human genes 0.000 claims abstract description 159
- 102100031618 HLA class II histocompatibility antigen, DP beta 1 chain Human genes 0.000 claims abstract description 137
- 108010045483 HLA-DPB1 antigen Proteins 0.000 claims abstract description 137
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 61
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 claims abstract description 43
- 108010061311 HLA-DRB3 Chains Proteins 0.000 claims abstract description 43
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims abstract description 41
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims abstract description 41
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 claims abstract description 39
- 108010040960 HLA-DRB4 Chains Proteins 0.000 claims abstract description 39
- 210000004027 cell Anatomy 0.000 claims description 76
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 76
- 206010028980 Neoplasm Diseases 0.000 claims description 49
- 108091033319 polynucleotide Proteins 0.000 claims description 40
- 102000040430 polynucleotide Human genes 0.000 claims description 40
- 239000002157 polynucleotide Substances 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 36
- 102000043131 MHC class II family Human genes 0.000 claims description 30
- 108091054438 MHC class II family Proteins 0.000 claims description 30
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims description 29
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 101100117565 Oryza sativa subsp. japonica DRB4 gene Proteins 0.000 claims description 25
- 239000013604 expression vector Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 10
- PFBPIHUEFUNOIS-DVQPEGLTSA-N (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-carbamimidamido-2-[[(2S)-2,6-diaminohexanoyl]amino]pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoyl]amino]-3-(1H-imidazol-4-yl)propanoic acid Chemical compound CSCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O PFBPIHUEFUNOIS-DVQPEGLTSA-N 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 abstract description 4
- 102210010945 HLA-DRB1*0901 Human genes 0.000 abstract description 2
- 108010053362 HLA-DRB1*04:06 antigen Proteins 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 description 56
- 102100037850 Interferon gamma Human genes 0.000 description 54
- 210000001744 T-lymphocyte Anatomy 0.000 description 43
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 37
- 230000006698 induction Effects 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 22
- 238000007792 addition Methods 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- 230000000638 stimulation Effects 0.000 description 19
- 108700028369 Alleles Proteins 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 101150034979 DRB3 gene Proteins 0.000 description 16
- 101100278514 Oryza sativa subsp. japonica DRB2 gene Proteins 0.000 description 16
- 239000000178 monomer Substances 0.000 description 16
- 230000003834 intracellular effect Effects 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 13
- 230000004913 activation Effects 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 238000012258 culturing Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 201000005787 hematologic cancer Diseases 0.000 description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108010010378 HLA-DP Antigens Proteins 0.000 description 6
- 102000015789 HLA-DP Antigens Human genes 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000003501 co-culture Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010024996 HLA-DRB1*04:05 antigen Proteins 0.000 description 3
- 102000043129 MHC class I family Human genes 0.000 description 3
- 108091054437 MHC class I family Proteins 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 2
- 108010046732 HLA-DR4 Antigen Proteins 0.000 description 2
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 201000003115 germ cell cancer Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101100297345 Caenorhabditis elegans pgl-2 gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010075101 HLA-DRB1*14:01 antigen Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- FHKZHRMERJUXRJ-DCAQKATOSA-N His-Ser-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CN=CN1 FHKZHRMERJUXRJ-DCAQKATOSA-N 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 1
- GGAPIOORBXHMNY-ULQDDVLXSA-N Lys-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)O GGAPIOORBXHMNY-ULQDDVLXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- IOVBCLGAJJXOHK-SRVKXCTJSA-N Ser-His-His Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IOVBCLGAJJXOHK-SRVKXCTJSA-N 0.000 description 1
- 229940126530 T cell activator Drugs 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 102000046004 human WT1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- -1 pcDNA3.1 Proteins 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
Definitions
- the present invention relates to a method for activating helper T cells, comprising the step of activating helper T cells by adding WT1 peptide to antigen-presenting cells, wherein the WT1 peptide comprises HLA-DRB1 * 0101 molecule, HLA -DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA- DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, HLA-DPB1 * 0201 molecule or HLA-DPB1 * Methods having the ability to bind to any MHC
- WT1 gene (Wilms' tumor 1 gene) has been identified as a causative gene of Wilms tumor, which is a renal cancer of children, and encodes a transcription factor having a zinc finger structure (Non-patent Documents 1 and 2). Subsequent studies have shown that it functions as an oncogene in hematopoietic tumors and solid tumors (Non-Patent Documents 3 to 6).
- CTLs cytotoxic T cells
- helper T cells are induced and activated by recognizing complexes of MHC class II molecules of antigen-presenting cells and antigenic peptides. Activated helper T cells assist B cell proliferation, differentiation, and maturation by producing cytokines such as IL-2, IL-4, IL-5, IL-6, or interferon. Such helper T cells have a function of activating the immune system by promoting the proliferation and activation of B cells and T cells. Therefore, helper T cells are mediated through MHC class II-binding antigen peptides in cancer immunotherapy. It is suggested that it is useful to enhance the function of cells and enhance the effect of cancer vaccine (Non-patent Document 9).
- WT1 peptide a specific peptide having a part of an amino acid sequence encoding a WT1 protein (hereinafter, also referred to as WT1 peptide in this specification) can bind to a plurality of MHC class II molecules and activate a helper T cell. It was shown that helper peptides exist (Patent Documents 5 and 6). However, it has been extremely difficult to verify whether this WT1 peptide has an effect on other MHC class II molecules because there are many types of MHC class II molecules.
- the problem to be solved by the present invention is to apply a specific WT1 peptide to a wide range of MHC class II molecule-positive subjects to activate helper T cells, to activate cytotoxic T cells, It is intended to provide a cytotoxic T cell activation inducer, a pharmaceutical composition for treating / preventing cancer, and the like.
- a peptide having the amino acid sequence: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His is HLA-DRB1 * 0101 molecule, HLA- DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, HLA-D It has been found that it binds to PB1 * 0201 molecule, HLA-DP
- the present invention (1) A method for activating helper T cells, comprising the step of activating helper T cells by adding WT1 peptide to antigen-presenting cells, wherein the WT1 peptide comprises HLA-DRB1 * 0101 molecule, HLA- DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * A method that has the ability to bind to an MHC class II molecule of any of the 0101 molecule, HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule; (2) WT1 peptide is HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB
- the WT1 peptide is a peptide comprising the amino acid sequence: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His (SEQ ID NO: 2), a variant or modification thereof, (1) to (1) 4) the method according to any one of (6)
- a composition comprising a WT1 peptide for activating a helper T cell by adding a WT1 peptide to an antigen-presenting cell, wherein the WT1 peptide comprises an HLA-DRB1 * 0101 molecule, an HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101
- a composition having the ability to bind to an MHC class
- the composition according to any one of (8), (10) The WT1 peptide is a peptide comprising the amino acid sequence: Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His (SEQ ID NO: 2), a variant or modification thereof, (6) to (6) 9)
- the composition according to any one of (11) An antigen-presenting cell in which a complex of an antigen peptide containing a WT1 peptide and an MHC class II molecule is presented, wherein the MHC class II molecule is an HLA-DRB1 * 0101 molecule or an HLA-DRB1 * 0401 molecule HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, An antigen presenting
- FIG. 1 shows PBMCs derived from various donors pulsed with WT1-332, T cells derived from PBMCs derived from provider 1 (HLA-DRB1 * 0406/1201, DRB3 * 0101, DRB4 * 0103 positive) The results of measuring the amount of IFN- ⁇ after co-culture are shown.
- the vertical axis represents the amount of IFN- ⁇ (pg / mL) in the supernatant after culturing.
- the horizontal axis shows the types of HLA-DRB1, 3 and 4 molecules that are positive in various donors.
- FIG. 2 shows PBMCs derived from donors (HLA-DRB1 * 0901/1101, DRB3 * 0202, DRB4 * 0103 positive) derived from PBMCs pulsed with WT1-332 and T cells derived from PBMCs.
- the results of measuring the amount of IFN- ⁇ after co-culture are shown.
- the vertical axis represents the amount of IFN- ⁇ (pg / mL) in the supernatant after culturing.
- the horizontal axis shows the types of HLA-DRB1, 3 and 4 molecules that are positive in various donors.
- FIG. 3 shows co-culture of T cells derived from PBMC derived from provider 3 (HLA-DRB1 * 0401/0405, DRB4 * 0102/0103 positive) with PBMCs derived from various donors pulsed with WT1-332 Then, the results of measuring the amount of IFN- ⁇ are shown.
- the vertical axis represents the amount of IFN- ⁇ (pg / mL) in the supernatant after culturing.
- the horizontal axis shows the types of HLA-DRB1 and 4 molecules that are positive in various positive donors.
- FIG. 4 shows PBMCs derived from various donors pulsed with WT1-332, T cells derived from PBMCs derived from provider 4 (HLA-DRB1 * 0901/1101, DRB3 * 0202, DRB4 * 0103 positive) The results of measuring the amount of IFN- ⁇ after co-culture are shown.
- the vertical axis represents the amount of IFN- ⁇ (pg / mL) in the supernatant after culturing.
- the horizontal axis shows the types of HLA-DRB1, 3 and 4 molecules that show positive in various positive donors.
- HLA-class II monomer proteins (DRB1 * 0101, DRB1 * 0405, DRB1 * 1501, DRB1 * 1502, DRB1 * 0803, DRB1 * 0901 and DRB4 * 0101) and various peptides were specifically associated.
- the vertical axis indicates the retention time mobility (minutes).
- the horizontal axis indicates the type of HLA-class II monomer protein.
- the bar graph indicates the type of peptide added (from the left, negative control ( ⁇ ), positive control ( ⁇ ), WT 1-332 (hatched square)).
- FIG. 6 shows T cells derived from PBMC derived from healthy blood donors (a total of 42 persons having at least one HLA-DRB1 * 1501, 1502, 0405, HLA-DPB1 * 0501, 0901). Shows that the WT1-332-specific Th1 ratio (CD4 positive / intracellular IFN- ⁇ positive cell ratio) increases significantly over time.
- the vertical axis represents the ratio (%) of the number of CD4 positive / intracellular IFN- ⁇ positive cells in the living cells, and the horizontal axis represents the culture days (days).
- ⁇ represents the ratio in the sample induced by addition of WT1-332 (WT1-332 induction group), and ⁇ represents the ratio in the sample induced by addition of solvent (control) (solvent induction group).
- FIG. 7 shows T cells derived from PBMCs derived from healthy blood donors (total 42 people having at least one HLA-DRB1 * 1501, 1502, 0405, HLA-DPB1 * 0501, 0901) Shows that the number of CTL cells specific to WT1 -332 (the ratio of CD8 positive / IFN- ⁇ positive cells) increases significantly over time.
- the vertical axis represents the ratio (%) of the number of CD8 positive / intracellular IFN- ⁇ positive cells in the living cells
- the horizontal axis represents the number of days of culture (days).
- FIG. 8 shows HLA-DR restriction of 17 specimens (providers 21 to 37) in which WT1-332 specific Th1 was induced in FIGS.
- WT1-332-specific IFN- ⁇ production was observed, and the IFN- ⁇ production was determined by anti-HLA-DR antibody.
- WT1-332-specific IFN- ⁇ production was determined by anti-HLA-DR antibody.
- the vertical axis represents the provider number (providers 21 to 37), and the horizontal axis represents the IFN- ⁇ production (pg / mL).
- ⁇ indicates the amount of IFN- ⁇ production after WT1-332 stimulation
- hatched ⁇ indicates the amount of IFN- ⁇ production after WT1-332 + anti-HLA-DR antibody stimulation
- ⁇ indicates that after solvent (control) stimulation
- FIG. 9 shows T cells on day 14 after induction of WT1-332 addition in 17 samples (providers 21 to 37) in which HLA-DR-restricted WT1-332-specific Th1 was induced in FIGS.
- FIG. 10 shows T cells 14 days after induction of WT1-332 addition in each of 17 samples (providers 21 to 37) in which HLA-DR-restricted WT1-332-specific Th1 was induced in FIGS.
- FIG. 11 shows the HLA-DP restriction of 9 samples (providers 38 to 46) in which WT1-332-specific Th1 was induced in FIGS.
- T cells on the 14th day after induction of addition of WT1-332 were stimulated with WT1-332, WT1-332-specific IFN- ⁇ production was observed, and the IFN- ⁇ production was determined by anti-HLA-DR antibody.
- WT1-332-specific IFN- ⁇ production was observed, and the IFN- ⁇ production was determined by anti-HLA-DR antibody.
- anti-HLA-DQ antibody was added and cultured, it was not suppressed.
- T cells induced by WT1-332 are HLA-DP restricted.
- the vertical axis represents the provider number (providers 38 to 46), and the horizontal axis represents the IFN- ⁇ production (pg / mL).
- ⁇ indicates the amount of IFN- ⁇ produced after WT1-332 stimulation
- hatched ⁇ indicates the amount of IFN- ⁇ produced after stimulation with WT1 -332 + anti-HLA-DR antibody
- vertical line (dashed line) ⁇ indicates WT1 -332+ IFN- ⁇ production after stimulation with anti-HLA-DQ antibody is shown
- ⁇ shows IFN- ⁇ production after solvent (control) stimulation.
- FIG. 12 shows T cells on day 14 after induction of WT1-332 addition in each of nine samples (providers 38 to 46) in which HLA-DP-restricted WT1-332-specific Th1 was induced in FIGS.
- FIG. 13 shows the results of T cells 14 days after induction of WT1-332 addition in each of 9 samples (providers 38 to 46) in which HLA-DP-restricted WT1-332-specific Th1 was induced in FIGS.
- the ratio of WT1-332-specific CTL cells increases.
- the vertical axis represents the donor number (providers 38 to 46), and the horizontal axis represents the ratio (%) of the number of CD8 positive / intracellular IFN- ⁇ positive cells in the living cells.
- ⁇ indicates the ratio after WT1-332 stimulation, and ⁇ indicates the ratio after solvent (control) stimulation.
- the present invention provides a method for activating a helper T cell or cytotoxic T cell, comprising adding a WT1 peptide to an antigen-presenting cell and activating the helper T cell or cytotoxic T cell.
- a method is provided wherein the WT1 peptide is capable of binding to an MHC class II molecule.
- the step of activating cytotoxic T cells may be performed through a step of activating helper T cells.
- the WT1 peptide used in the present invention includes HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 It has the ability to bind to any MHC class II molecule of the molecule, HLA-DPB1 * 0901 molecule, HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule.
- the WT1 peptide used in the present invention may also have the ability to bind to at least two or more of the MHC class II molecules. Further, the WT1 peptide used in the present invention may have the ability to bind to any MHC class II molecule among, for example, HLA-DR molecule, HLA-DQ and HLA-DP molecule.
- the WT1 peptide may be a peptide having a part of the amino acid sequence of the human WT1 protein represented by SEQ ID NO: 1.
- the amino acid sequence and length are not specifically limited, However, When a peptide is too long, it will become easy to receive the effect
- the length of the peptide of the present invention is preferably 10 to 25 amino acids, more preferably 15 to 21 amino acids, still more preferably 16 to 20 amino acids, for example, 16 amino acids, 17 amino acids, 18 amino acids, or 19 amino acids.
- Specific examples of the peptides of the present invention include the amino acid sequence: Lys Arg Tyr Phe Lys Leu Ser His His Leu Gln Met His Ser Arg Lys His (SEQ ID NO: 2).
- the WT1 peptide used in the present invention includes a variant of the above peptide.
- a variant of the above peptide for example, in the amino acid sequence shown in SEQ ID NO: 2, several variants, for example, 1 to 9, preferably 1 to 5, 1 to 4, 1 to 3, more preferably 1 to Two, more preferably one amino acid may comprise a peptide selected from the group consisting of peptides having an amino acid sequence substituted, deleted or added.
- Amino acid substitution in the peptide may be performed with any kind of amino acid at any position, and conservative amino acid substitution is preferred. Examples of conservative amino acid substitutions include Glu residues as Asp residues, Phe residues as Tyr residues, Leu residues as Ile residues, Ala residues as Ser residues, and His residues.
- a preferred specific example of the peptide of the present invention is that having SEQ ID NO: 2, but any of the peptides described above is HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 Molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule , HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, either
- the peptide of the present invention may also be a modified form of the above amino acid sequence.
- An amino acid residue in the amino acid sequence can be modified by a known method.
- Such a modified product may be, for example, a functional group in the side chain of an amino acid residue subjected to esterification, alkylation, halogenation, phosphorylation, or the like.
- various substances can be bound to the N-terminus and / or C-terminus of the peptide containing the amino acid sequence.
- amino acids, peptides, analogs thereof and the like may be bound.
- a histidine tag may be added, and it may be a fusion protein together with a protein such as thioredoxin.
- a detectable label may be attached to the WT1 peptide.
- these substances are bound to the peptide of the present invention, these substances are treated with, for example, an in vivo enzyme or a process such as intracellular processing, and finally a peptide having the above amino acid sequence is generated.
- the effect of inducing helper T cells and / or cytotoxic T cells can be obtained by being presented on the cell surface as a complex with MHC class II molecules.
- These substances may regulate the solubility of the peptide of the present invention, may improve the stability such as protease resistance, and are specific for a given tissue / organ, for example.
- the peptide of the present invention may be delivered, or it may have an action of enhancing the uptake efficiency of antigen-presenting cells.
- These substances may also be those that increase the ability to induce CTL, for example, helper peptides other than the peptides of the present invention.
- the WT1 peptide used in the present invention can be synthesized using a method usually used in the art or a modification thereof. Such synthetic methods include, for example, Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol 2, Academic Press Inc., New York, 1976; Peptide Synthesis, Maruzen Co., Ltd., 1975; Maruzen Co., Ltd., 1985; Drug Development, Vol. 14, Peptide Synthesis, Hirokawa Shoten, 1991, etc.
- the peptide used in the present invention can also be produced using genetic engineering techniques based on the nucleotide sequence information encoding the peptide. Such genetic engineering techniques are well known to those skilled in the art. These techniques can be carried out according to the methods described in the literature (Molecular Cloning, T. Maniatis et al., CSH Laboratory (1983), DNA Cloning, DM DM Glover, IRL PRESS (1985)).
- the present invention also relates to a polynucleotide sequence encoding the WT1 peptide described above.
- the polynucleotide sequence encoding the WT1 peptide may be a DNA sequence or an RNA sequence. In the present invention, these polynucleotide sequences may be used instead of using the WT1 peptide. These polynucleotide sequences may be used by being incorporated into an appropriate vector. Examples of the vector include plasmids, phage vectors, virus vectors, and the like.
- the vector may appropriately have factors such as a promoter capable of inducing expression, a gene encoding a signal sequence, a marker gene for selection, and a terminator. Methods for introducing these genes into cells and living organisms, expression methods, and the like are known to those skilled in the art.
- the antigen-presenting cell used in the present invention is a cell capable of presenting an antigen peptide containing the WT1 peptide together with an MHC class II molecule to a helper T cell.
- an MHC class II molecule for example, dendritic cells, peripheral blood mononuclear cells, etc. means. Therefore, the subject from which the antigen-presenting cell used in the present invention is derived is the same molecule as the MHC class II molecule to which the added WT1 peptide can bind (eg, HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401).
- the addition of the WT1 peptide to the antigen-presenting cell can be performed directly by adding the WT1 peptide, or by adding a polynucleotide encoding the WT1 peptide or an expression vector containing the polynucleotide encoding the WT1 peptide, Alternatively, it may be performed indirectly by adding cells containing the expression vector. These additions can be performed by methods known in the art.
- the polynucleotide encoding the WT1 peptide, the expression vector containing the polynucleotide encoding the WT1 peptide, and the cell containing the expression vector can be obtained by techniques well known to those skilled in the art.
- the polynucleotide used in the present invention can be determined based on the amino acid sequence of the WT1 peptide (for example, the amino acid sequence shown in SEQ ID NO: 2).
- the polynucleotide can be produced by, for example, a DNA or RNA synthesis method, a PCR method, or the like.
- the type of expression vector containing the above-mentioned polynucleotide, the sequence contained in addition to the above-mentioned polynucleotide sequence, etc. can be appropriately selected according to the type, purpose, etc. of the host into which the expression vector is introduced, plasmid, phage vector, virus vector Etc.
- a cell containing the expression vector can be produced, for example, by transforming a host cell.
- host cells include E. coli, yeast, insect cells, animal cells and the like.
- a method for introduction into a host cell a usual method such as a calcium phosphate method, a DEAE-dextran method, an electroporation method, or a lipid for gene introduction can be used.
- helper T cells recognize TCR / CD3 complexes on the surface of T cells through antigen-presenting cell surface MHC class II molecules, and integrin on the surface of antigen-presenting cells is an integrin ligand on the surface of antigen-presenting cells. It is activated by being stimulated with.
- the activation of the helper T cell in this specification includes not only the activation of the helper T cell but also the induction and proliferation of the helper T cell.
- the helper T cells activated in the present invention may be undifferentiated T cells (for example, naive T cells). Activated helper T cells have a function of activating the immune system by promoting induction, proliferation, and activation of B cells and cytotoxic T cells.
- helper T cells activated in vitro using the method of the present invention can also be used for the treatment or prevention of cancer or the like, or as an adjuvant for these.
- Activation of helper T cells can be evaluated by measuring production and secretion amount of cytokines such as interferon (for example, interferon ⁇ ) and interleukin.
- the present invention provides a composition for activating helper T cells or cytotoxic T cells by adding WT1 peptide to antigen-presenting cells.
- the activation of cytotoxic T cells may be performed through the activation of helper T cells.
- the active ingredient contained in the composition of the present invention include a WT1 peptide, a polynucleotide encoding the WT1 peptide, a vector containing the polynucleotide, and a cell containing the vector, and the antigen containing the WT1 peptide as an antigen peptide. Any molecule may be used as long as it can be presented on the surface of the presenting cell. These factors can be obtained by methods well known to those skilled in the art as described above.
- the WT1 peptide used in the present invention includes HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA- DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * Having the ability to bind to either 0501 molecule, HLA-DPB1 * 0901 molecule, HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule.
- the WT1 peptide used in the present invention may have the ability to bind to at least two or more MHC class II molecules among the MHC class II molecules.
- the WT1 peptide used in the present invention may have the ability to bind to any MHC class II molecule among HLA-DR molecules, HLA-DQ, and HLA-DP molecules.
- composition of the present invention comprises HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA- DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, HLA-DPB1 * 0201 molecule or is administered to a subject having any one or more of the MHC class II molecules of HLA-DPB1 * 0301 molecule, helper T cells in the subject and / Other immune system is activated by the cytotoxic T cells are activated.
- the WT1 gene is also used in various cancers and tumors, for example, hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin Since it is highly expressed in solid cancers such as cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer, the composition of the present invention can also be used as an adjuvant for the treatment or prevention of cancer. Alternatively, helper T cells, cytotoxic T cells and the like activated using the composition of the present invention can be used, for example, as an adjuvant for the treatment of the cancer.
- helper T cells, cytotoxic T cells and the like activated using the composition of the present invention can be used, for example, as an adjuvant for the treatment of the cancer.
- the composition of the present invention contains, for example, a carrier, an excipient, or an additive in addition to the WT1 peptide, the polynucleotide encoding the WT1 peptide, a vector containing the polynucleotide, or a cell containing the vector. May be.
- the WT1 peptide or the like contained in the composition of the present invention includes a known MHC class I-restricted WT1 peptide because it activates helper T cells and / or cytotoxic T cells in a WT1 peptide-specific manner, Or you may apply with these.
- the application method of the composition of the present invention can be appropriately selected according to conditions such as the degree of activation of desired helper T cells and / or cytotoxic T cells, the state of antigen-presenting cells, and the like.
- Examples of the application method include intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration, nasal administration, oral administration, and the like, or addition to an antigen-presenting cell culture medium.
- the amount of the WT1 peptide and the like contained in the composition of the present invention, the form of the composition, the number of times of application, etc. are the degree of activation of the desired helper T cells and / or cytotoxic T cells, the state of antigen-presenting cells, etc. It can select suitably according to conditions.
- the present invention provides a method for treating or preventing cancer in a subject comprising the step of activating helper T cells or cytotoxic T cells by adding a WT1 peptide to antigen-presenting cells,
- the WT1 peptide is HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 Molecule, H Methods are provided that have the ability to bind to MHC class II molecules of either
- the method of the present invention is a method for activating a helper T cell and / or cytotoxic T cell to activate a subject's immune system to treat or prevent cancer in the subject.
- the step of activating cytotoxic T cells may be performed through a step of activating helper T cells.
- the addition of the WT1 peptide to the antigen-presenting cell can be performed directly by adding the WT1 peptide, by adding a polynucleotide encoding the WT1 peptide or a polynucleotide encoding the WT1 peptide, or the expression vector May be carried out indirectly by the addition of cells containing.
- the polynucleotide encoding the WT1 peptide, the expression vector containing the polynucleotide encoding the WT1 peptide, and the cell containing the expression vector can be obtained by methods well known to those skilled in the art as described above.
- HLA-DRB1 * 0101 molecule HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 Molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule , HLA-DPB1 * 0901 molecule, HLA-DPB1 * 0201 molecule, or HLA-DPB1 * 0301 molecule are MHC class II molecule-positive subjects.
- the cancer to which the present invention can be applied may be any, for example, hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cell Examples include solid cancers such as cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, and ovarian cancer.
- the method of the present invention may be used in combination with a method for treating or preventing cancer using a MHC class I molecule-restricted WT1 peptide or a pharmaceutical composition therefor.
- the present invention provides the use of a WT1 peptide, a polynucleotide encoding the WT1 peptide, a vector containing the polynucleotide, or a cell containing the vector for producing the above composition. Furthermore, the present invention provides a WT1 peptide, a polynucleotide encoding the WT1 peptide, a vector containing the polynucleotide, or a cell containing the vector, which is used for activating helper T cells or cytotoxic T cells. .
- the present invention provides the WT1 peptide, a polynucleotide encoding the WT1 peptide for activating helper T cells and / or cytotoxic T cells by adding a WT1 peptide to an antigen-presenting cell,
- a vector comprising a polynucleotide, a kit comprising a cell comprising the vector, wherein the WT1 peptide comprises HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, It has the ability to bind to any MHC class II
- the kit is used in the method for activating the helper T cell or cytotoxic T cell.
- the kit of the present invention may contain, for example, a means for obtaining antigen-presenting cells, a means for evaluating the activity of helper T cells and / or cytotoxic T cells, and the like.
- an instruction manual is attached to the kit. Helper T cells or cytotoxic T cells can be efficiently activated using the kit of the present invention.
- the present invention provides an antigen-presenting cell in which a complex of an antigen peptide containing a WT1 peptide and an MHC class II molecule is presented.
- the MHC class II molecule is HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 Molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule , HLA-DPB1 * 0901 molecule may be any of the HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule
- the antigen-presenting cells of the present invention may be prepared using techniques known among those skilled in the art. For example, a cell having antigen-presenting ability is isolated from a cancer patient, and the isolated cell is pulsed with the WT1 peptide (for example, a peptide having the amino acid sequence shown in SEQ ID NO: 2) or a polynucleotide encoding the WT1 peptide. Alternatively, an expression vector containing the polynucleotide may be introduced into a cell, and a complex of an antigen peptide containing a WT1 peptide and a MHC class II molecule may be presented on the cell surface (Cancer Immunol. Immunoother) 46:82, 1998, J.
- WT1 peptide for example, a peptide having the amino acid sequence shown in SEQ ID NO: 2
- an expression vector containing the polynucleotide may be introduced into a cell, and a complex of an antigen peptide containing a WT1 peptide
- the cell having an antigen presenting ability is not limited as long as it expresses an MHC class II molecule capable of presenting a WT1 peptide on the cell surface, but peripheral blood mononuclear having a high antigen presenting ability. Spheres or dendritic cells are preferred.
- the presence of the antigen-presenting cell of the present invention is confirmed by an increase in cytotoxic T cell activity that is confirmed by an increase in the amount of interferon ⁇ .
- the antigen-presenting cell of the present invention is effectively used in cell therapy (for example, dendritic cell therapy) as an active ingredient of a pharmaceutical composition.
- the present invention provides a helper T cell that recognizes a complex of an antigenic peptide containing a WT1 peptide and an MHC class II molecule.
- the MHC class II molecule is HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 Molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule , HLA-DPB1 * 0901 molecule may be any of the HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule.
- helper T cell of the present invention for example, an antigen peptide containing a peptide consisting of the amino acid sequence shown in SEQ ID NO: 2, HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, either MHC click of HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule
- a complex of scan II molecules can be exemplified recognizing help
- the present invention provides cytotoxic T cells that are activated by helper T cells that recognize a complex of an antigenic peptide comprising a WT1 peptide and an MHC class II molecule.
- the cytotoxic T cell of the present invention include an antigen peptide containing a peptide consisting of the amino acid sequence shown in SEQ ID NO: 2, HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA -DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA- DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA
- the cytotoxic T cell of the present invention can be easily prepared by a person skilled in the art by a known method.
- a patient's peripheral blood lymphocytes are isolated and in vitro with a peptide (for example, a peptide having the amino acid sequence shown in SEQ ID NO: 2), a polynucleotide encoding the peptide, or an expression vector containing the peptide. Produced by stimulation (Journal of Experimental Medicine 1999, 190: 1669).
- the cytotoxic T cells prepared as described above can be used as an active ingredient of a pharmaceutical composition for treating or preventing cancer or the like.
- cytotoxic T cell-inducing activity was observed in samples derived from subjects having certain MHC class molecules by administration of WT-332. This is because, in peripheral blood mononuclear cells, there are antigen-presenting cells in which a complex of an antigen peptide consisting of WT1 peptide and a MHC class II molecule is presented, and this antigen-presenting cell presenting this complex, This indicates that there are helper T cells that specifically recognize and cytotoxic T cells induced by helper T cells.
- the present invention provides an HLA tetramer having an antigenic peptide comprising the WT1 peptide and an MHC class II molecule.
- the MHC class II molecules are HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 molecule, HLA -DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, or HLA It may be any of the DPB1 * 0901 molecules and may be at least two or more of the above MHC class II molecules.
- the HLA tetramer means a tetramer obtained by biotinylating a complex (HLA monomer) in which an HLA protein is associated with a peptide and binding it to avidin.
- HLA tetramers those containing various antigen peptides are commercially available, and the HLA tetramers of the present invention can be easily prepared (Science 279: 2103-2106 (1998), Science 274: 94-96 (1996). )).
- the tetramer of the present invention is preferably fluorescently labeled so that the helper T cells and cytotoxic T cells of the present invention bound by known detection means such as flow cytometry and fluorescence microscope can be easily selected or detected. .
- the HLA tetramer in the present invention is not limited to a tetramer, and a multimer such as a pentamer or a dendrimer can be used as necessary.
- a multimer refers to a multimer obtained by combining two or more complexes (HLA monomers) in which an HLA protein is associated with a peptide using a known technique.
- the present invention activates a helper T cell or cytotoxic T cell comprising any one of the above composition, antigen-presenting cell, helper T cell, cytotoxic T cell or tetramer as an active ingredient.
- a pharmaceutical composition is provided.
- the pharmaceutical composition of the present invention may contain any one or more of the above compositions, antigen-presenting cells, helper T cells, cytotoxic T cells or tetramers as an active ingredient.
- the pharmaceutical composition of the present invention can be used for treating or preventing cancer.
- the pharmaceutical composition of the present invention comprises various cancers and tumors that express WT1, for example, hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cells It can be applied to solid cancers such as cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.
- WT1 hematopoietic tumors
- hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, breast cancer, germ cells
- solid cancers such as cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.
- the pharmaceutical composition of the present invention comprises HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA-DRB1 * 0901 Molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule , HLA-DPB1 * 0901 molecule, HLA-DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule can be used for administration to a subject having MHC class II molecules.
- the pharmaceutical composition of the present invention may be used in combination with other methods for treating or preventing cancer or pharmaceutical compositions therefor.
- the pharmaceutical composition of the present invention may contain a helper T cell or cytotoxic T cell activator, proliferator, inducer or the like, or contains a known MHC class I-restricted WT1 peptide. May be.
- the pharmaceutical composition of the present invention may contain, for example, a carrier, an excipient and the like in addition to the active ingredient.
- the administration method of the pharmaceutical composition of the present invention can be appropriately selected according to conditions such as the type of disease, the state of the subject, and the target site. Examples of the method include, but are not limited to, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration, nasal administration, and oral administration.
- the amount of the active ingredient contained in the pharmaceutical composition of the present invention, the dosage form of the pharmaceutical composition, the number of administrations, and the like can be appropriately selected according to conditions such as the type of disease, the condition of the subject, and the target site.
- the present invention treats cancer, comprising the step of administering to a subject an effective amount of any of the above compositions, antigen-presenting cells, helper T cells, cytotoxic T cells or tetramers.
- a method for prevention wherein the subject is HLA-DRB1 * 0101 molecule, HLA-DRB1 * 0401 molecule, HLA-DRB1 * 0403 molecule, HLA-DRB1 * 0406 molecule, HLA-DRB1 * 0803 molecule, HLA- DRB1 * 0901 molecule, HLA-DRB1 * 1101 molecule, HLA-DRB3 * 0202 molecule, HLA-DRB4 * 0101 molecule, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * Methods are provided that have MHC class II molecules of either 0901 molecules, HLA-DPB1
- Cancers that can be treated or prevented by the method of the present invention include various cancers and tumors that express WT1, for example, hematopoietic tumors such as leukemia, myelodysplastic syndrome, multiple myeloma, malignant lymphoma, stomach cancer, colon cancer, lung cancer, Solid cancers such as breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.
- the method of the present invention may be used in combination with other methods for treating or preventing cancer, for example, methods for treating or preventing cancer using a known MHC class I molecule-restricted WT1 peptide.
- the present invention provides the use of any of the above compositions, antigen presenting cells, helper T cells, cytotoxic T cells or tetramers for producing the above pharmaceutical compositions. Furthermore, the present invention provides the above-mentioned composition, antigen-presenting cell, helper T cell, cytotoxic T cell or tetramer used to activate a helper T cell or cytotoxic T cell. The present invention further provides the above composition, antigen-presenting cell, helper T cell, cytotoxic T cell or tetramer used for the treatment or prevention of cancer.
- the present invention relates to an antibody (hereinafter also referred to as an anti-WT1 antibody) that specifically binds to the WT1 peptide or a polynucleotide encoding the WT1 peptide.
- the antibody of the present invention may be a polyclonal antibody or a monoclonal antibody. Specific examples include an antibody that specifically binds to a peptide having the amino acid sequence shown in SEQ ID NO: 2. Methods for producing these antibodies are already well known, and the antibodies of the present invention can also be produced according to these conventional methods (Current protocols Molecular Biology edit. Ausubel et al. (1987) Publish. John Wiley and Sons.
- a peptide having the amino acid sequence shown in SEQ ID NO: 2 can be used as an immunogen to immunize a non-human animal such as a rabbit, and obtained from the serum of this animal by a conventional method.
- a non-human animal such as a rabbit
- a monoclonal antibody a non-human animal such as a mouse is immunized with the peptide (peptide having the amino acid sequence shown in SEQ ID NO: 2) used in the present invention, and the obtained spleen cells and myeloma cells are immunized.
- the anti-WT1 antibody of the present invention can also be prepared by enhancing immunological reaction using various adjuvants depending on the host. Examples of such an adjuvant include mineral gels (for example, Freund's adjuvant, aluminum hydroxide, etc.), surface active substances, human adjuvants and the like.
- the anti-WT1 antibody of the present invention can be used for affinity chromatography, immunological diagnosis and the like.
- the immunological diagnosis can be appropriately selected from immunoblotting, radioimmunoassay (RIA), enzyme immunoassay (ELISA), fluorescence or luminescence assay.
- the present invention relates to HLA-DRB1 * 0101, HLA-DRB1 * 0401, HLA-DRB1 * 0403, HLA-DRB1 * 0406, HLA-DRB1 * 0803, HLA-DRB1 * 0901, HLA-DRB1 * 1101 , HLA-DRB3 * 0202, HLA-DRB4 * 0101, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, HLA- A method for determining the presence or amount of a WT1 peptide in a MHC class II molecule positive subject of either DPB1 * 0201 molecule or HLA-DPB1 * 0301 molecule comprising: (A) reacting a sample obtained from the subject with the anti-WT1 antibody; (B) examining the presence or amount of the anti-WT
- Samples used in the step (a) include HLA-DRB1 * 0101, HLA-DRB1 * 0401, HLA-DRB1 * 0403, HLA-DRB1 * 0406, HLA-DRB1 * 0803, HLA-DRB1 * 0901, HLA-DRB1 * 1101, HLA-DRB3 * 0202, HLA-DRB4 * 0101, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, Those obtained from subjects having MHC class II molecules of either HLA-DPB1 * 0201 molecules or HLA-DPB1 * 0301 molecules can be used.
- the sample used in the step (a) examples include body fluids such as blood and lymphocytes, and tissues.
- Obtaining a sample, reaction with an antibody, and the like can be appropriately performed by those skilled in the art using known techniques.
- the step (b) in the present invention includes, for example, determining the localization, site, amount, etc. of the anti-WT1 antibody, it can be used for cancer diagnosis, prognosis diagnosis and the like.
- the anti-WT1 antibody may be labeled.
- a known label such as a fluorescent label or a radioactive label can be used. By labeling, the presence or amount of the WT1 peptide can be determined easily and rapidly.
- the present invention relates to a kit for determining the presence or amount of a WT1 peptide comprising the anti-WT1 antibody as an essential component.
- the kit of the present invention may contain, for example, an anti-WT1 antibody acquisition means, an evaluation means, and the like.
- an instruction manual is attached to the kit.
- the present invention in still another aspect, is HLA-DRB1 * 0101, HLA-DRB1 * 0401, HLA-DRB1 * 0403, HLA-DRB1 * 0406, HLA-DRB1 * 0803, HLA-DRB1 * 0901, HLA-DRB1 * 1101, HLA-DRB3 * 0202, HLA-DRB4 * 0101, HLA-DRB1 * 1501 molecule, HLA-DRB1 * 0405 molecule, HLA-DRB1 * 1502 molecule, HLA-DPB1 * 0501 molecule, HLA-DPB1 * 0901 molecule, HLA -DPB1 * 0201 molecule or determining the presence or amount of WT1-specific helper T cells or WT1-specific cytotoxic T cells in any of the MHC class II molecules positive subjects of HLA-DPB1 * 0301 molecule A that way, (A) stimulating a sample obtained from said subject with WT1 peptide; (B) examining the presence or amount
- the sample of the present invention may be any sample as long as it contains antigen-presenting cells.
- the sample used in the present invention may be derived from a healthy person or a cancer patient. By using these cells derived from a healthy person, for example, it is possible to diagnose whether or not the patient is suffering from or has a predisposition to cancer. By using these cells derived from cancer patients, for example, it is possible to predict whether WT1 immunotherapy has an effect in cancer patients.
- the obtained sample may be cultured before and after stimulation with the WT1 peptide, and the culture conditions can be appropriately determined by those skilled in the art. Stimulation of these cells with the WT1 peptide can be performed using a known technique such as electroporation, and can be performed either in vitro or in vivo. Cytokine production, helper T cells, and cytotoxic T cell responses exist, or cytokine production, helper T cells, or cytotoxic T cell responses can be determined by known methods.
- the present invention relates to a kit for determining the presence or amount of a WT1 peptide, which contains the WT1 peptide as an essential component.
- the kit of the present invention may contain, for example, a sample obtaining means, an evaluation means such as a cytokine, and the like.
- an instruction manual is attached to the kit.
- PBMC PBMC
- WT 1-332 peptide consisting of the amino acid sequence shown in SEQ ID NO: 2
- IL-7 PeproTech
- cryopreserved PBMC was thawed, pulsed with 10 ⁇ g / mL WT1-332, treated with 50 ⁇ g / mL mitomycin C (Kyowa Hakko Kirin), and transferred to a new 24-well plate at 1.0 ⁇ 10 6 to Seeding was performed at 1.6 ⁇ 10 6 cells / well.
- the cells that had been cultured for 1 week were collected and seeded in wells seeded with antigen-presenting cells at 1.0 ⁇ 10 6 to 1.6 ⁇ 10 6 cells / well.
- IL-7 was added to each well at 10 ng / mL and cultured at 37 ° C. and 5% CO 2 .
- IFN- ⁇ response inhibition in anti-HLA-DR antibody
- T cells derived from PBMCs of donors 1 to 4 were used in the absence of WT1 -332, 10 ⁇ g / mL WT1 -332, 10 ⁇ g / mL WT1 -332 and 10 ⁇ g / mL anti-HLA-DR antibody (BD) Cultured for 24 hours in the presence. After culturing, the amount of IFN- ⁇ in the supernatant was quantified by ELISA (BD). As a result, it was shown that all induced T cells recognize WT1 -332 and produce IFN- ⁇ , and that the response is HLA-DR molecule restricted.
- IFN- ⁇ determination of restraint allele
- T cells derived from donor 1 PBMC were co-cultured for 24 hours with antigen-presenting cells from donors 5, 6, 7, 8, 9 pulsed with 10 ⁇ g / mL WT 1-332. After the culture, the amount of IFN- ⁇ in the supernatant was quantified by ELISA. The results are shown in FIG. The donor 1-derived T cells produce IFN- ⁇ when cocultured with HLA-DR4 (DRB1 * 0403, 0406) positive antigen-presenting cells, indicating that the restricted allele is HLA-DRB1 * 0406 It was done. It was also shown that HLA-DRB1 * 0403 can present WT1-332 and stimulate T cells.
- T cells derived from donor 2 PBMC were co-cultured with donor 10, 11, 12, 9 derived antigen-presenting cells pulsed with 10 ⁇ g / mL WT 1-332 for 24 hours. After the culture, the amount of IFN- ⁇ in the supernatant was quantified by ELISA. The results are shown in FIG. Donor 2-derived T cells produce IFN- ⁇ when co-cultured with HLA-DRB3 * 0202 positive antigen-presenting cells, indicating that the restricted allele is HLA-DRB3 * 0202.
- T cells derived from donor 3 PBMC were co-cultured with donor 13, 14, 15, 10 derived antigen-presenting cells pulsed with 10 ⁇ g / mL WT 1-332 for 24 hours. After the culture, the amount of IFN- ⁇ in the supernatant was quantified by ELISA. The results are shown in FIG. Donor 3 derived T cells produced IFN- ⁇ when co-cultured with HLA-DR4 (DRB1 * 0401, 0405) positive antigen presenting cells. Therefore, it was shown that both HLA-DRB1 * 0401 and 0405 can present WT1-332 and stimulate T cells.
- T cells derived from donor 4 PBMCs were co-cultured for 24 hours with donor 16, 11, 17, 18, 19, 20 derived antigen-presenting cells pulsed with 10 ⁇ g / mL WT1-332. After the culture, the amount of IFN- ⁇ in the supernatant was quantified by ELISA. The results are shown in FIG. Donor 4-derived T cells produce IFN- ⁇ when co-cultured with HLA-DRB1 * 1101-positive antigen presenting cells, indicating that the restricted allele is HLA-DRB1 * 1101.
- HLA class II monomer proteins DRB1 * 1501, 0101, 0405, 0803, 0901, 1502, or DRB4 were used by using HPLC. * 0101) and WT 1-332 were subjected to a folding test. Briefly, a HLA class II monomer protein, a peptide (a peptide that binds to each protein (positive control), a peptide that does not bind (negative control), and WT1-332), a folding buffer are mixed to prepare a folding reaction solution, After the reaction at 37 ° C., the retention time using HPLC was analyzed. Folding with WT1-332 was evaluated using the shift in retention time due to the binding of HLA class II monomer protein and peptide. The reagents used in this test are shown in the following table. (Table 1. Reagents used in the test)
- HLA class II monomer protein stored frozen at 80 ° C. was thawed on ice. Thawed HLA class II monomer protein was prepared in a dilution buffer so that 0.05 mg (1 ⁇ 10 ⁇ 9 mol) was contained in 83 ⁇ L.
- PBMC Blood mononuclear cells
- WT1-332 was added to a well inoculated with PBMC at 20 ⁇ g / mL and IL-7 (PeproTeck) at 10 ng / mL, followed by culturing at 37 ° C., 5% CO 2 for 1 week.
- a group solvent induction group in which a solvent (10 mM acetic acid) was added to a final concentration of 10 ⁇ M instead of WT1-332 was set.
- a part of the separated PBMC was stored frozen for antigen-presenting cells at the time of restimulation. One week later (day 7), restimulation was performed.
- PBMCs thawed frozen PBMCs were thawed, pulsed with 20 ⁇ g / mL WT1-332 or 10 ⁇ M acetic acid solvent, treated with 50 ⁇ g / mL mitomycin C (Kyowa Hakko Kirin Co., Ltd.), and transferred to a new 24-well plate. Seeding was performed at ⁇ 10 6 to 1.6 ⁇ 10 6 cells / well. Next, the cells that had been cultured for 1 week were collected and seeded in wells seeded with antigen-presenting cells at 1.0 ⁇ 10 6 to 1.6 ⁇ 10 6 cells / well. Finally, IL-7 was added to each well at 10 ng / mL and cultured at 37 ° C. and 5% CO 2 .
- IFN- ⁇ Intracellular cytokine staining (ICS)
- ICS Intracellular cytokine staining
- FIG. 7 shows that the WT1-332 specific CTL also increased over time in the WT1-332 induction group from day 7 to day 14, and the increase was also significant compared to the solvent induction group. (P ⁇ 0.0001).
- IFN- ⁇ reaction inhibition in anti-HLA-DR antibody and anti-HLA-DQ antibody
- T cells derived from PBMCs of donors 21-37 were treated with 20 ⁇ g / mL WT1-332 and 10 ⁇ g / mL anti-HLA-DR antibody in the presence of 10 ⁇ M solvent, 20 ⁇ g / mL WT1-332 ( L243 [G46-6], BD) was cultured for 24 hours. After culturing, the amount of IFN- ⁇ in the supernatant was quantified by ELISA (BD). The results are shown in FIG.
- T cells derived from PBMCs of donors 38 to 46 were treated with 20 ⁇ g / mL WT1-332 and 10 ⁇ g / mL anti-HLA-DR in the presence of 20 ⁇ g / mL WT1-332 in the presence of 10 ⁇ M solvent.
- the cells were cultured for 24 hours in the presence of antibody (L243 [G46-6], BD), 10 ⁇ g / mL anti-HLA-DQ antibody (SPVL3, BC).
- HLA-DRB1 * 1501, 1502, 0405, HLA-DPB1 * 0501, 0901 in total, 42 in total HLA-DR
- Table 2 shows HLA class II types (types of HLA-DRB1 and HLA-DPB1 alleles) of 17 specimens (providers 21 to 37).
- DRB3 * 0202 is in linkage disequilibrium with DRB1 * 1101, DRB1 * 1401, and DRB1 * 1405 (DRB1 allele indicated by ⁇ in the table), and DRB4 * 0101 is DRB1 * 0403, DRB1 * 0405, DRB1 * 0901. And a linkage disequilibrium (DRB1 allele indicated by ⁇ in the table).
- alleles shown in bold italic letters represent the new matched HLA-DRB1 allele.
- FIG. 9 From FIG. 9, FIG. 10, and Table 2, induction of WT1-332-specific Th1 and WT1-332-specific CTL was observed in cells having these HLA-DR alleles.
- results using the healthy blood donors (HLA-DRB1 * 1501, 1502, 0405, HLA-DPB1 * 0501, 0901 in total, total 42 persons) in FIGS.
- Results for day 14 are shown in FIGS. 12 and 13 for each of nine specimens (providers 38-46) in which -DP-restricted and WT1-332 specific Th1 was induced.
- Table 3 shows the HLA class II type (types of HLA-DRB1 and HLA-DPB1 alleles) of each of nine specimens (providers 38 to 46).
- * represents a compatible HLA-DPB1 allele known so far.
- FIG. 12 From FIG. 12, FIG. 13 and Table 3, induction of WT1-332-specific Th1 and WT1-332-specific CTL was observed in cells having these HLA-DP alleles.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
Description
(1)WT1ペプチドを抗原提示細胞に添加して、ヘルパーT細胞を活性化させる工程を含む、ヘルパーT細胞の活性化方法であって、該WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子に結合する能力を有するものである方法、
(2)WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子およびHLA-DPB1*0301分子のうちの少なくとも2つのMHCクラスII分子に結合する能力を有するものである、(1)記載の方法、
(3)WT1ペプチドが、さらに、HLA-DRB1*0405分子、HLA-DRB1*1501分子、HLA-DRB1*1502分子、HLA-DPB1*0501分子および/またはHLA-DPB1*0901分子に結合する能力を有するものである、(1)または(2)記載の方法、
(4)WT1ペプチドの抗原提示細胞への添加が、WT1ペプチド、WT1ペプチドをコードするポリヌクレオチド、該ポリペプチドを含む発現ベクター、または該発現ベクターを含む細胞の添加により行われる、(1)から(3)のいずれか1つ記載の方法、
(5)WT1ペプチドが、アミノ酸配列:Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His(配列番号:2)を含むペプチド、その変異体または修飾体である、(1)~(4)のいずれか1つ記載の方法、
(6)WT1ペプチドを抗原提示細胞に添加して、ヘルパーT細胞を活性化させるための、WT1ペプチドを含む組成物であって、該WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子に結合する能力を有するものである組成物、
(7)WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子およびHLA-DPB1*0301分子のうちの少なくとも2つのMHCクラスII分子に結合する能力を有するものである、(6)記載の組成物、
(8)WT1ペプチドが、さらに、HLA-DRB1*0405分子、HLA-DRB1*1501分子、HLA-DRB1*1502分子、HLA-DPB1*0501分子および/またはHLA-DPB1*0901分子に結合する能力を有するものである、(6)または(7)記載の組成物、
(9)WT1ペプチドの抗原提示細胞への添加が、WT1ペプチド、WT1ペプチドをコードするポリヌクレオチド、該ポリヌクレオチドを含む発現ベクター、または該発現ベクターを含む細胞の添加により行われる、(6)~(8)のいずれか1つ記載の組成物、
(10)WT1ペプチドが、アミノ酸配列:Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His(配列番号:2)を含むペプチド、その変異体または修飾体である、(6)~(9)のいずれか1つ記載の組成物、
(11)WT1ペプチドを含む抗原ペプチドとMHCクラスII分子との複合体が提示されている抗原提示細胞であって、前記MHCクラスII分子が、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子である、抗原提示細胞、
(12)WT1ペプチドを含む抗原ペプチドとMHCクラスII分子との複合体を認識するヘルパーT細胞であって、前記MHCクラスII分子が、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子である、ヘルパーT細胞、
(13)(11)記載のヘルパーT細胞により活性化される、細胞傷害性T細胞、
(14)(6)~(10)のいずれか1つ記載の組成物、(11)記載の抗原提示細胞、(12)記載のヘルパーT細胞、または(13)記載の細胞傷害性T細胞のいずれかを有効成分として含む、癌を治療または予防するための医薬組成物、
(15)WT1ペプチド、WT1ペプチドをコードするポリヌクレオチド、該ポリヌクレオチドを含む発現ベクター、または該発現ベクターを含む細胞のいずれかを有効成分として含む、細胞傷害性T細胞を活性化させるための医薬組成物であって、HLA-DPB1*0501分子、HLA-DPB1*0901分子、HLA-DPB1*0201分子、HLA-DPB1*0301分子、HLA-DRB1*1501分子、HLA-DRB1*1502分子、HLA-DRB1*0405分子、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、またはHLA-DRB4*0101分子のうちのいずれかのMHCクラスII分子を有する対象に投与するための医薬組成物、
(16)WT1ペプチドに特異的に結合する抗体であって、該WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子に結合する能力を有するものである抗体、
(17)HLA-DRB1*0101、HLA-DRB1*0401、HLA-DRB1*0403、HLA-DRB1*0406、HLA-DRB1*0803、HLA-DRB1*0901、HLA-DRB1*1101、HLA-DRB3*0202、HLA-DRB4*0101、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子陽性対象におけるWT1特異的ヘルパーT細胞の存在または量を決定する方法であって、
(a)前記対象から取得した試料をWT1ペプチドを用いて刺激し、
(b)サイトカインまたはヘルパーT細胞の存在または量を調べる、
工程を含み、サイトカインまたはヘルパーT細胞の存在または量の増大がWT1特異的ヘルパーT細胞の存在または量を示すものである方法、
を提供する。
(a)前記対象から取得した試料を上記抗WT1抗体と反応させ、次いで、
(b)前記試料に含まれる上記抗WT1抗体の存在または量を調べる、
工程を含む方法を提供する。前記工程(a)において用いられる試料として、HLA-DRB1*0101、HLA-DRB1*0401、HLA-DRB1*0403、HLA-DRB1*0406、HLA-DRB1*0803、HLA-DRB1*0901、HLA-DRB1*1101、HLA-DRB3*0202、HLA-DRB4*0101、HLA-DRB1*1501分子、HLA-DRB1*0405分子、HLA-DRB1*1502分子、HLA-DPB1*0501分子、HLA-DPB1*0901分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子を有する対象から取得されたものを用いることができる。前記工程(a)に用いられる試料は、例えば、血液、リンパ球などの体液、組織などを挙げることができる。試料の取得や抗体との反応などは、当業者であれば公知の手法を用いて適宜行うことができる。本発明における工程(b)は、例えば、上記抗WT1抗体の局在、部位、量等を決定することを含むので、癌の診断、予後診断などに用いることができる。上記抗WT1抗体は標識されていてもよい。標識としては、蛍光標識、放射性標識などの公知のものを使用することができる。標識することによりWT1ペプチドの存在または量の決定を簡便かつ迅速に行うことが可能となる。
(a)前記対象から取得した試料をWT1ペプチドを用いて刺激し、
(b)サイトカイン、ヘルパーT細胞または細胞傷害性T細胞の存在または量を調べる、
工程を含み、サイトカイン、ヘルパーT細胞または細胞傷害性T細胞の存在または量の増大がWT1特異的ヘルパーT細胞またはWT1特異的細胞傷害性T細胞の存在または量を示すものである方法を提供する。本発明の試料は、抗原提示細胞を含むものであればいかなるものであってもよく、例えば、末梢血単核球、浸潤性リンパ球、腫瘍細胞、腹水中の細胞、胸水中の細胞、脳脊髄液中の細胞、骨髄細胞、またはリンパ節細胞などを挙げることができる。本発明に用いられる試料は、健常人由来であっても、あるいは癌患者由来であってもよい。健常人由来のこれらの細胞を用いることにより、例えば、癌に罹患しているかどうか、あるいはその素因を有するかどうかを診断することなどが可能になる。癌患者由来のこれらの細胞を用いることにより、例えば、癌患者においてWT1免疫療法が効果を有するかどうかを予測することなどが可能になる。本発明の方法において、取得した試料は、WT1ペプチドによる刺激の前後に培養されていてもよく、前記培養条件は当業者が適宜決定することができる。WT1ペプチドを用いたこれらの細胞の刺激は、エレクトロポレーションなどの公知の手法を用いて行うことができ、インビトロまたはインビボのいずれにおいて行われてもよい。サイトカイン産生、ヘルパーT細胞、細胞傷害性T細胞の反応が存在するか、あるいはサイトカイン産生量、ヘルパーT細胞、または細胞傷害性T細胞の反応量は既知の方法により調べることができる。
健常人の血液提供者(提供者1:HLA-DRB1*0406/1201、DRB3*0101、DRB4*0103陽性、提供者2:HLA-DRB1*0901/1101、DRB3*0202、DRB4*0103陽性、提供者3:HLA-DRB1*0401/0405、DRB4*0102/0103陽性、提供者4:HLA-DRB1*0901/1101、DRB3*0202、DRB4*0103陽性)の末梢血より末梢血単核球(PBMC)を分離した。分離したPBMC(1.5×107個)を45% RPMI-1640(SIGMA社)、45% AIM-V(invitrogen社)、10% AB型ヒト血清(MP Biomedicals社)より組成される培地へ懸濁し、1.5×106個/ウェルで24ウェルプレートへ播種した(0日目)。PBMCを播種したウェルへWT1-332(配列番号:2に示すアミノ酸配列からなるペプチド)を10μg/mL、IL-7(PeproTech社)を10ng/mLとなるように添加し、37℃、5% CO2で1週間培養した。また、分離したPBMCの一部を再刺激時の抗原提示細胞用に凍結保存した。
健常人の血液提供者(提供者5:HLA-DRB1*0406/1201、DRB3*0101、DRB4*0103陽性、提供者6:HLA-DRB1*0403/1405、DRB3*0202、DRB4*0103陽性、提供者7:HLA-DRB1*0403/1201、DRB3*0101、DRB4*0103陽性、提供者8:HLA-DRB1*0101/0901、DRB4*0103陽性、提供者9:HLA-DRB1*1401/1406、DRB3*0202陽性、提供者10:HLA-DRB1*0803/0901、DRB4*0103陽性、提供者11:HLA-DRB1*1101/1502、DRB3*0202陽性、提供者12:HLA-DRB1*0405/1406、DRB3*0202、DRB4*0103陽性、提供者13:HLA-DRB1*0401/0405、DRB4*0102/0103陽性、提供者14:HLA-DRB1*0401/1502、DRB4*0102陽性、提供者15:HLA-DRB1*0101/0405、DRB4*0103陽性、提供者16:HLA-DRB1*0901/1501、DRB4*0103陽性、提供者17:HLA-DRB1*0405/1501、DRB4*0103陽性、提供者18:HLA-DRB1*1401/1502、DRB3*0202陽性、提供者19:HLA-DRB1*1403/1502、DRB3*0101陽性、提供者20:HLA-DRB1*0803/1302、DRB3*0301陽性)の末梢血よりPBMCを分離し、拘束アレル決定実験に用いる抗原提示細胞とした。それぞれのPBMCを、使用するまで-80℃にて凍結保存した。
提供者1~4のPBMCより誘導されたT細胞を、WT1-332非存在下、10μg/mL WT1-332存在下、10μg/mL WT1-332および10μg/mL 抗HLA-DR抗体(BD社)存在下で24時間培養した。培養後、上清中のIFN-γ量をELISA(BD社)にて定量した。その結果、誘導されたすべてのT細胞がWT1-332を認識してIFN-γを産生すること、またその反応はHLA-DR分子拘束的であることが示された。
提供者1~4のPBMCより誘導されたT細胞をそれぞれ適当なWT1-332でパルスした抗原提示細胞と反応させ、誘導されたT細胞の拘束アレルを決定した。
提供者1のPBMCより誘導されたT細胞を、10μg/mL WT1-332でパルスした提供者5、6、7、8、9由来抗原提示細胞と24時間共培養した。培養後、上清中のIFN-γ量をELISAにて定量した。結果を図1に示す。提供者1由来T細胞は、HLA-DR4(DRB1*0403、0406)陽性抗原提示細胞と共培養したときにIFN-γを産生することから、拘束アレルはHLA-DRB1*0406であることが示された。また、HLA-DRB1*0403がWT1-332を提示してT細胞を刺激できることも示された。
提供者2のPBMCより誘導されたT細胞を、10μg/mL WT1-332でパルスした提供者10、11、12、9由来抗原提示細胞と24時間共培養した。培養後、上清中のIFN-γ量をELISAにて定量した。結果を図2に示す。提供者2由来T細胞は、HLA-DRB3*0202陽性抗原提示細胞と共培養したときにIFN-γを産生することから、拘束アレルはHLA-DRB3*0202であることが示された。
提供者3のPBMCより誘導されたT細胞を、10μg/mL WT1-332でパルスした提供者13、14、15、10由来抗原提示細胞と24時間共培養した。培養後、上清中のIFN-γ量をELISAにて定量した。結果を図3に示す。提供者3由来T細胞は、HLA-DR4(DRB1*0401、0405)陽性抗原提示細胞と共培養したときにIFN-γを産生した。よって、HLA-DRB1*0401、0405共にWT1-332を提示してT細胞を刺激できることが示された。
提供者4のPBMCより誘導されたT細胞を、10μg/mL WT1-332でパルスした提供者16、11、17、18、19、20由来抗原提示細胞と24時間共培養した。培養後、上清中のIFN-γ量をELISAにて定量した。結果を図4に示す。提供者4由来T細胞は、HLA-DRB1*1101陽性抗原提示細胞と共培養したときにIFN-γを産生することから、拘束アレルはHLA-DRB1*1101であることが示された。
(表1.試験に用いる試薬類)
-80℃に凍結保存してあるHLAクラスIIモノマータンパク質を氷上で融解した。融解したHLAクラスIIモノマータンパク質を83μL中に0.05mg(1×10-9mol)含まれるように希釈バッファーで調製した。
各ペプチドを電子天秤で約1mg秤量し,ガラスバイアルに移し20mg/mLになるようにDMSOで溶解した。
HLAクラスIIモノマータンパク質に対し50倍モル量となるペプチド量を以下の計算式で算出した。
必要なペプチド量:1×10-9mol×50=5×10-8mol(必要なペプチド量)
5×10-8×(ペプチド分子量)×1000=(必要なペプチド量)(mg)
(必要なペプチド量)/[ペプチド純度/100]=(添加するペプチド量)(mg)
[(添加するペプチド量)/20mg/mL]×1000=(添加するペプチド溶液量)(μL)
フォールディングbufferとして、HLAクラスIIモノマータンパク質とペプチドの混合溶液の10%量を添加した。フォールディングbuffer添加量を以下の計算式で算出した。
[83μL(HLAクラスIIモノマータンパク質量)+(50倍モル量のペプチド溶液量)]×0.1=フォールディングbuffer添加量
HLAクラスIIモノマータンパク質が入ったガラスバイアルに、算出して得られたペプチド溶液、フォールディングbufferを添加し、37℃で一晩静置した。HLPC(Waters 2695 Separation Module)を起動し、Seperdex 200カラムを平衡化bufferで平衡化した。すべてのサンプルに平衡化bufferを300μL加え、よく混合し、そのうち100μLをSample injection volumeとし、保持時間を算出した。分析時間を50分とした。HLAクラスIIモノマータンパク質とペプチドがフォールディングした基準は、保持時間がコントロール(溶媒のみ)と比べ0.1分以上移動したものとした。その結果、調べた7種類のHLAクラスIIモノマータンパク質(DRB1*1501、0101、0405、0803、0901、1502、またはDRB4*0101)で保持時間の移動度が0.1分以上上昇したことから(図5)、これらのタンパク質に対してWT1-332が特異的に結合し、抗原提示できることが明らかとなった。
健常人の血液提供者(HLA-DRB1*1501、1502、0405、HLA-DPB1*0501、0901を少なくとも1つ以上有する、計延べ42人)の末梢血より末梢血単核球(PBMC)を分離した。分離したPBMCを1.2×107個ずつ分割し、45% RPMI-1640(SIGMA社)、45% AIM-V(invitrogen社)、10% AB型ヒト血清(MP Biomedicals社)より組成される培地へ懸濁し、1.5×106個/ウェルで24ウェルプレートへ播種した(0日目)。PBMCを播種したウェルへWT1-332を20μg/mL、IL-7(PeproTeck社)を10ng/mLとなるように添加し、37℃、5% CO2で1週間培養した。対照群としてWT1-332の代わりに溶媒(10mM 酢酸)を最終濃度10μMになるように添加した群(溶媒誘導群)を設定した。また、分離したPBMCの一部を再刺激時の抗原提示細胞用に凍結保存した。
1週間後(7日目)、再刺激を行った。まず、凍結保存しておいたPBMCを解凍し、20μg/mL WT1-332または10μM酢酸溶媒でパルスし、50μg/mL マイトマイシンC(協和発酵キリン社)で処理し、新しい24ウェルプレートへ1.0×106~1.6×106個/ウェルで播種した。次に、1週間培養していた細胞を回収し、1.0×106~1.6×106個/ウェルで抗原提示細胞を播種したウェルへ播種した。最後に、IL-7を10ng/mLとなるように各ウェルに添加し、37℃、5% CO2で培養した。2日後(9日目」)、各ウェルの培養液を半量静かに抜き取り、代わりに40U/mL IL-2(PeproTech社)含有培地を添加して培養を続けた。その後、1日おきに20U/mL IL-2含有培地で培養液の半量交換操作を行った。
0、7、14日目に細胞を回収し、IFN-γ測定実験に使用した。
0日目においては、調製後のPBMC、7日目及び14日目においては、WT1-332誘導群及び溶媒誘導群より回収した生細胞を96ウェルU底プレートへ播種、及びWT1-332含有培地を最終濃度20μg/mLとなるように添加して抗原再刺激を入れた。また、比較対照として溶媒含有培地を最終濃度10μMとなるように添加した。37℃、5%CO2で4時間培養した後、Brefeldin A(BioLegend)を添加してさらに培養を続けた。培養開始から6時間後に細胞を回収し、PE標識抗ヒトCD4抗体、FITC標識抗ヒトCD8抗体で染色した。細胞内IFN-γ染色を、BD Cytofix/Cytoperm Fixation/Permiabilization Kit(Becton Dickinson)とPerCP/Cy5.5標識抗ヒトIFN-γ抗体を用いて行った。解析はEPICS-XL MCL(Beckman Coulter)を用いた。結果を図6および7に示す。図6より、WT1-332誘導群において、7日目から14日目の間において、WT1-332特異的Th1の顕著な増加が確認され、経時的に増加することがわかった。この増加は溶媒誘導群に比して有意な増加であった(P<0.0001)。また、図7より、WT1-332特異的CTLに関しても7日目から14日目の間に、WT1-332誘導群において経時的な増加が確認され、その増加も溶媒誘導群に比して有意であった(P<0.0001)。
14日目において、提供者21~37のPBMCより誘導されたT細胞を、10μM 溶媒存在下、20μg/mL WT1-332存在下、20μg/mL WT1-332および10μg/mL 抗HLA-DR抗体(L243[G46-6]、BD社)存在下で24時間培養した。培養後、上清中のIFN-γ量をELISA(BD社)にて定量した。結果を図8に示す。提供者21~37の検体において、誘導されたT細胞がWT1-332を認識してIFN-γを産生すること、またその反応はHLA-DR分子拘束的であることが示された。
また、14日目において、提供者38~46のPBMCより誘導されたT細胞を、10μM 溶媒存在下、20μg/mL WT1-332存在下、20μg/mL WT1-332および10μg/mL 抗HLA-DR抗体(L243[G46-6]、BD社)、10μg/mL 抗HLA-DQ抗体(SPVL3、BC社)存在下で24時間培養した。培養後、上清中のIFN-γ量をELISA(BD社)にて定量した。結果を図11に示す。提供者38~46の検体において、誘導されたT細胞がWT1-332を認識してIFN-γを産生し、その反応は抗HLA-DR抗体、抗HLA-DQ抗体で阻害されなかった。これらのことから、提供者38~46に由来するWT1-332誘導T細胞がHLA-DP分子拘束的であることが示された。
図6及び7における健常人の血液提供者(HLA-DRB1*1501、1502、0405、HLA-DPB1*0501、0901を少なくとも1つ以上有する、計延べ42人)を用いた結果において、HLA-DR拘束性且つWT1-332特異的Th1が誘導された17人の検体(提供者21~37)それぞれについて、14日目の結果を図9および10に示す。また、17人の検体(提供者21~37)それぞれのHLAクラスII型(HLA-DRB1及びHLA-DPB1アレルの型)を以下の表2に示す。ここで、DRB3*0202はDRB1*1101、DRB1*1401及びDRB1*1405と連鎖不平衡にあり(表中、△で示すDRB1アレル)、DRB4*0101はDRB1*0403、DRB1*0405、DRB1*0901と連鎖不平衡にある(表中、▲で示すDRB1アレル)。表中、太字斜体の文字で示すアレルは新規適合HLA-DRB1アレルを表す。
Claims (17)
- WT1ペプチドを抗原提示細胞に添加して、ヘルパーT細胞を活性化させる工程を含む、ヘルパーT細胞の活性化方法であって、該WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子に結合する能力を有するものである方法。
- WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子およびHLA-DPB1*0301分子のうちの少なくとも2つのMHCクラスII分子に結合する能力を有するものである、請求項1記載の方法。
- WT1ペプチドが、さらに、HLA-DRB1*0405分子、HLA-DRB1*1501分子、HLA-DRB1*1502分子、HLA-DPB1*0501分子および/またはHLA-DPB1*0901分子に結合する能力を有するものである、請求項1または2記載の方法。
- WT1ペプチドの抗原提示細胞への添加が、WT1ペプチド、WT1ペプチドをコードするポリヌクレオチド、該ポリペプチドを含む発現ベクター、または該発現ベクターを含む細胞の添加により行われる、請求項1から3のいずれか1項記載の方法。
- WT1ペプチドが、アミノ酸配列:Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His(配列番号:2)を含むペプチド、その変異体または修飾体である、請求項1~4のいずれか1項記載の方法。
- WT1ペプチドを抗原提示細胞に添加して、ヘルパーT細胞を活性化させるための、WT1ペプチドを含む組成物であって、該WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子に結合する能力を有するものである組成物。
- WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子およびHLA-DPB1*0301分子のうちの少なくとも2つのMHCクラスII分子に結合する能力を有するものである、請求項6記載の組成物。
- WT1ペプチドが、さらに、HLA-DRB1*0405分子、HLA-DRB1*1501分子、HLA-DRB1*1502分子、HLA-DPB1*0501分子および/またはHLA-DPB1*0901分子に結合する能力を有するものである、請求項6または7記載の組成物。
- WT1ペプチドの抗原提示細胞への添加が、WT1ペプチド、WT1ペプチドをコードするポリヌクレオチド、該ポリヌクレオチドを含む発現ベクター、または該発現ベクターを含む細胞の添加により行われる、請求項6~8のいずれか1項記載の組成物。
- WT1ペプチドが、アミノ酸配列:Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His(配列番号:2)を含むペプチド、その変異体または修飾体である、請求項6~9のいずれか1項記載の組成物。
- WT1ペプチドを含む抗原ペプチドとMHCクラスII分子との複合体が提示されている抗原提示細胞であって、前記MHCクラスII分子が、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子である、抗原提示細胞。
- WT1ペプチドを含む抗原ペプチドとMHCクラスII分子との複合体を認識するヘルパーT細胞であって、前記MHCクラスII分子が、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子である、ヘルパーT細胞。
- 請求項12記載のヘルパーT細胞により活性化される、細胞傷害性T細胞。
- 請求項6~10のいずれか1項記載の組成物、請求項11記載の抗原提示細胞、請求項12記載のヘルパーT細胞、または請求項13記載の細胞傷害性T細胞のいずれかを有効成分として含む、癌を治療または予防するための医薬組成物。
- WT1ペプチド、WT1ペプチドをコードするポリヌクレオチド、該ポリヌクレオチドを含む発現ベクター、または該発現ベクターを含む細胞のいずれかを有効成分として含む、細胞傷害性T細胞を活性化させるための医薬組成物であって、HLA-DPB1*0501分子、HLA-DPB1*0901分子、HLA-DPB1*0201分子、HLA-DPB1*0301分子、HLA-DRB1*1501分子、HLA-DRB1*1502分子、HLA-DRB1*0405分子、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、またはHLA-DRB4*0101分子のうちのいずれかのMHCクラスII分子を有する対象に投与するための医薬組成物。
- WT1ペプチドに特異的に結合する抗体であって、該WT1ペプチドが、HLA-DRB1*0101分子、HLA-DRB1*0401分子、HLA-DRB1*0403分子、HLA-DRB1*0406分子、HLA-DRB1*0803分子、HLA-DRB1*0901分子、HLA-DRB1*1101分子、HLA-DRB3*0202分子、HLA-DRB4*0101分子、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子に結合する能力を有するものである抗体。
- HLA-DRB1*0101、HLA-DRB1*0401、HLA-DRB1*0403、HLA-DRB1*0406、HLA-DRB1*0803、HLA-DRB1*0901、HLA-DRB1*1101、HLA-DRB3*0202、HLA-DRB4*0101、HLA-DPB1*0201分子またはHLA-DPB1*0301分子のうちのいずれかのMHCクラスII分子陽性対象におけるWT1特異的ヘルパーT細胞の存在または量を決定する方法であって、
(a)前記対象から取得した試料をWT1ペプチドを用いて刺激し、
(b)サイトカインまたはヘルパーT細胞の存在または量を調べる、
工程を含み、サイトカインまたはヘルパーT細胞の存在または量の増大がWT1特異的ヘルパーT細胞の存在または量を示すものである方法。
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020197008457A KR102079480B1 (ko) | 2010-10-05 | 2011-10-04 | 헬퍼 t 세포의 활성화 방법 |
SG2013025622A SG189287A1 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
KR1020207004213A KR102171794B1 (ko) | 2010-10-05 | 2011-10-04 | 헬퍼 t 세포의 활성화 방법 |
JP2012537718A JP6134139B2 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーt細胞の活性化方法 |
EP11830662.0A EP2626418B8 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
BR112013008230A BR112013008230A2 (pt) | 2010-10-05 | 2011-10-04 | método para ativar célula t auxiliar |
CA2813557A CA2813557C (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
NZ609460A NZ609460A (en) | 2010-10-05 | 2011-10-04 | Method for activating helper t cell |
CN201180058552.2A CN103298928B (zh) | 2010-10-05 | 2011-10-04 | 用于激活辅助性t细胞的方法 |
KR1020137011554A KR20140009168A (ko) | 2010-10-05 | 2011-10-04 | 헬퍼 t 세포의 활성화 방법 |
MX2013003884A MX361299B (es) | 2010-10-05 | 2011-10-04 | Metodo para activar celulas auxiliares. |
AU2011313327A AU2011313327B2 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper T cell |
US13/877,768 US10654892B2 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper T cell |
ES11830662T ES2849187T3 (es) | 2010-10-05 | 2011-10-04 | Método para activar células T auxiliares |
EA201390509A EA037547B1 (ru) | 2010-10-05 | 2011-10-04 | Способ активации хелперных т-клеток |
IL225536A IL225536B (en) | 2010-10-05 | 2013-04-02 | A method for activating a t-helper cell |
ZA2013/03056A ZA201303056B (en) | 2010-10-05 | 2013-04-25 | Method for activating helper t cell |
IL245440A IL245440A0 (en) | 2010-10-05 | 2016-05-03 | A method for activating a t-helper cell |
US16/835,761 US20200354405A1 (en) | 2010-10-05 | 2020-03-31 | Method for activating helper t cell |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-225806 | 2010-10-05 | ||
JP2010225806 | 2010-10-05 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/877,768 A-371-Of-International US10654892B2 (en) | 2010-10-05 | 2011-10-04 | Method for activating helper T cell |
US16/835,761 Division US20200354405A1 (en) | 2010-10-05 | 2020-03-31 | Method for activating helper t cell |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012046730A1 true WO2012046730A1 (ja) | 2012-04-12 |
Family
ID=45927725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/072874 WO2012046730A1 (ja) | 2010-10-05 | 2011-10-04 | ヘルパーt細胞の活性化方法 |
Country Status (20)
Country | Link |
---|---|
US (2) | US10654892B2 (ja) |
EP (1) | EP2626418B8 (ja) |
JP (3) | JP6134139B2 (ja) |
KR (3) | KR102079480B1 (ja) |
CN (2) | CN103298928B (ja) |
AR (1) | AR083295A1 (ja) |
AU (1) | AU2011313327B2 (ja) |
BR (1) | BR112013008230A2 (ja) |
CA (1) | CA2813557C (ja) |
CO (1) | CO6710946A2 (ja) |
EA (1) | EA037547B1 (ja) |
ES (1) | ES2849187T3 (ja) |
IL (2) | IL225536B (ja) |
MX (2) | MX361299B (ja) |
MY (1) | MY170306A (ja) |
NZ (2) | NZ703560A (ja) |
SG (3) | SG189287A1 (ja) |
TW (2) | TWI608099B (ja) |
WO (1) | WO2012046730A1 (ja) |
ZA (1) | ZA201303056B (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014042226A1 (ja) * | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
WO2014098012A1 (ja) * | 2012-12-17 | 2014-06-26 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
WO2015129790A1 (ja) * | 2014-02-26 | 2015-09-03 | 株式会社バイオイミュランス | Wt1抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
WO2018088439A1 (ja) | 2016-11-09 | 2018-05-17 | 国立大学法人大阪大学 | T細胞集団の改変方法 |
US10124046B2 (en) | 2003-11-05 | 2018-11-13 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US10139395B2 (en) | 2007-02-27 | 2018-11-27 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Wt1由来ペプチドのコンジュゲート体およびこれを含む組成物 |
US10947503B2 (en) | 2014-12-25 | 2021-03-16 | International Institute Of Cancer Immunology, Inc. | Method for modifying T cell population |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
ES2849187T3 (es) * | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CN116789792A (zh) | 2013-01-15 | 2023-09-22 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
DK2982681T3 (en) | 2013-03-29 | 2018-12-10 | Sumitomo Dainippon Pharma Co Ltd | WT1 ANTIGENPEPTIDKONJUGATVACCINE |
CN106565836B (zh) * | 2015-10-10 | 2020-08-18 | 中国科学院广州生物医药与健康研究院 | 高亲和力的可溶性pdl-1分子 |
US20200016255A1 (en) * | 2016-11-30 | 2020-01-16 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides |
CA3091099C (en) * | 2018-02-15 | 2021-11-23 | National University Corporation Asahikawa Medical University | Cancer antigen peptide |
WO2020041501A1 (en) * | 2018-08-22 | 2020-02-27 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
WO2005045027A1 (ja) | 2003-11-05 | 2005-05-19 | International Institute Of Cancer Immunology, Inc. | Wt1由来のhla−dr結合性抗原ペプチド |
WO2005095598A1 (ja) | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
WO2007097358A1 (ja) | 2006-02-22 | 2007-08-30 | International Institute Of Cancer Immunology, Inc. | Hla-a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 |
WO2008105462A1 (ja) | 2007-02-27 | 2008-09-04 | International Institute Of Cancer Immunology, Inc. | ヘルパーt細胞の活性化方法およびそのための組成物 |
WO2010123065A1 (ja) * | 2009-04-23 | 2010-10-28 | 株式会社癌免疫研究所 | 癌抗原ヘルパーペプチド |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5726288A (en) | 1989-11-13 | 1998-03-10 | Massachusetts Institute Of Technology | Localization and characterization of the Wilms' tumor gene |
CN1560078B (zh) | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
CA2349442C (en) | 1998-09-30 | 2012-12-04 | Corixa Corporation | Compositions and methods for wt1 specific immunotherapy |
US7063854B1 (en) | 1998-09-30 | 2006-06-20 | Corixa Corporation | Composition and methods for WTI specific immunotherapy |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
CA2401070A1 (en) | 2000-02-22 | 2001-08-30 | Corixa Corporation | Compositions and methods for diagnosis and therapy of malignant mesothelioma |
CA2440303C (en) | 2001-03-22 | 2013-03-19 | Haruo Sugiyama | Wt1 modified peptide |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
WO2003002142A1 (en) | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes |
JPWO2003028758A1 (ja) | 2001-09-28 | 2005-01-13 | 治夫 杉山 | 抗原特異的t細胞の誘導方法 |
US8735357B2 (en) | 2001-09-28 | 2014-05-27 | International Institute Of Cancer Immunology, Inc. | Method of inducing antigen-specific T cells |
ES2538486T3 (es) | 2002-09-12 | 2015-06-22 | International Institute Of Cancer Immunology, Inc. | Preparación de péptidos antigénicos contra el cáncer |
ATE442378T1 (de) | 2002-09-20 | 2009-09-15 | Int Inst Cancer Immunology Inc | Substituierte wt1-peptide |
US20060217297A1 (en) | 2003-01-15 | 2006-09-28 | Haruo Sugiyama | Dimerized peptide |
ES2478446T3 (es) | 2003-06-27 | 2014-07-22 | International Institute Of Cancer Immunology, Inc. | Método de selección de pacientes candidatos para la vacuna contra WT1 |
US7608769B2 (en) * | 2004-05-12 | 2009-10-27 | First Act, Inc. | Packaged drum set |
JP4719876B2 (ja) | 2005-04-04 | 2011-07-06 | 国立大学法人愛媛大学 | Hlaクラスii拘束性wt1抗原ペプチド |
AU2006304573B2 (en) | 2005-10-17 | 2012-05-24 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
CN101336249A (zh) | 2005-11-30 | 2008-12-31 | 株式会社癌免疫研究所 | 新型肽化合物 |
US7420880B2 (en) | 2005-12-29 | 2008-09-02 | Timex Group B.V. | Multimode electronic device with calibrating/setting mechanism |
EP3117836A1 (en) | 2006-04-10 | 2017-01-18 | Sloan Kettering Institute For Cancer Research | Immunogenic wt-1 peptides and uses thereof |
CA2886619A1 (en) | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same |
EP3173480A3 (en) | 2007-03-05 | 2017-08-16 | International Institute of Cancer Immunology, Inc. | Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
ES2849187T3 (es) * | 2010-10-05 | 2021-08-16 | Int Inst Cancer Immunology Inc | Método para activar células T auxiliares |
JP6530192B2 (ja) | 2012-12-17 | 2019-06-12 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
-
2011
- 2011-10-04 ES ES11830662T patent/ES2849187T3/es active Active
- 2011-10-04 KR KR1020197008457A patent/KR102079480B1/ko active IP Right Grant
- 2011-10-04 SG SG2013025622A patent/SG189287A1/en unknown
- 2011-10-04 CN CN201180058552.2A patent/CN103298928B/zh active Active
- 2011-10-04 NZ NZ703560A patent/NZ703560A/en unknown
- 2011-10-04 US US13/877,768 patent/US10654892B2/en active Active
- 2011-10-04 TW TW100135857A patent/TWI608099B/zh active
- 2011-10-04 AR ARP110103676A patent/AR083295A1/es unknown
- 2011-10-04 JP JP2012537718A patent/JP6134139B2/ja active Active
- 2011-10-04 AU AU2011313327A patent/AU2011313327B2/en active Active
- 2011-10-04 SG SG10201508252PA patent/SG10201508252PA/en unknown
- 2011-10-04 MY MYPI2013001197A patent/MY170306A/en unknown
- 2011-10-04 CN CN201610191489.4A patent/CN105802910A/zh active Pending
- 2011-10-04 WO PCT/JP2011/072874 patent/WO2012046730A1/ja active Application Filing
- 2011-10-04 SG SG10202108581TA patent/SG10202108581TA/en unknown
- 2011-10-04 BR BR112013008230A patent/BR112013008230A2/pt not_active Application Discontinuation
- 2011-10-04 KR KR1020207004213A patent/KR102171794B1/ko active IP Right Grant
- 2011-10-04 CA CA2813557A patent/CA2813557C/en active Active
- 2011-10-04 TW TW105107752A patent/TW201623616A/zh unknown
- 2011-10-04 EP EP11830662.0A patent/EP2626418B8/en active Active
- 2011-10-04 KR KR1020137011554A patent/KR20140009168A/ko not_active Application Discontinuation
- 2011-10-04 EA EA201390509A patent/EA037547B1/ru unknown
- 2011-10-04 MX MX2013003884A patent/MX361299B/es active IP Right Grant
- 2011-10-04 NZ NZ609460A patent/NZ609460A/en unknown
-
2013
- 2013-04-02 IL IL225536A patent/IL225536B/en not_active IP Right Cessation
- 2013-04-05 MX MX2018008436A patent/MX2018008436A/es unknown
- 2013-04-25 ZA ZA2013/03056A patent/ZA201303056B/en unknown
- 2013-05-03 CO CO13111246A patent/CO6710946A2/es unknown
-
2016
- 2016-05-03 IL IL245440A patent/IL245440A0/en unknown
- 2016-05-31 JP JP2016109398A patent/JP6298101B2/ja active Active
-
2017
- 2017-12-12 JP JP2017237964A patent/JP2018093870A/ja active Pending
-
2020
- 2020-03-31 US US16/835,761 patent/US20200354405A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Hla−a24拘束性癌抗原ペプチド |
WO2005045027A1 (ja) | 2003-11-05 | 2005-05-19 | International Institute Of Cancer Immunology, Inc. | Wt1由来のhla−dr結合性抗原ペプチド |
WO2005095598A1 (ja) | 2004-03-31 | 2005-10-13 | International Institute Of Cancer Immunology, Inc. | Wt1由来の癌抗原ペプチド |
WO2007097358A1 (ja) | 2006-02-22 | 2007-08-30 | International Institute Of Cancer Immunology, Inc. | Hla-a*3303拘束性wt1ペプチド、およびそれを含む医薬組成物 |
WO2008105462A1 (ja) | 2007-02-27 | 2008-09-04 | International Institute Of Cancer Immunology, Inc. | ヘルパーt細胞の活性化方法およびそのための組成物 |
WO2010123065A1 (ja) * | 2009-04-23 | 2010-10-28 | 株式会社癌免疫研究所 | 癌抗原ヘルパーペプチド |
Non-Patent Citations (34)
Title |
---|
"Antibodies; A Laboratory Manual", 1989, COLD SPRING HARBER LABORATORY PRESS |
"Basis and Experiments of Peptide Synthesis", 1985, MARUZEN CO., LTD. |
"Current protocols in Molecular Biology", 1987, JOHN WILEY AND SONS |
"Peptide Synthesis", 1966, INTERSCIENCE |
"Peptide Synthesis", 1975, MARUZEN CO., LTD. |
"Peptide Synthesis", vol. 14, 1991, HIROKAWA SHOTEN CO., article "Development of Medicines" |
"The Proteins", vol. 2, 1976, ACADEMIC PRESS INC. |
CALL KM ET AL., CELL, vol. 60, no. 3, 9 February 1990 (1990-02-09), pages 509 - 20 |
CANCER IMMUNOL. IMMUNOTHER., vol. 46, 1998, pages 82 |
CANCER RES., vol. 56, 1996, pages 5672 |
CANCER RES., vol. 59, 1999, pages 1184 |
DANIEL A. HABER ET AL., CELL, vol. 61, no. 7, 29 June 1990 (1990-06-29), pages 1257 - 69 |
DM. GLOVER: "DNA Cloning", 1985, IRL PRESS |
FUJIKI F. ET AL.: "A WT1 protein-derived, naturally processed 16-mer peptide, WT1322, is a promiscuous helper peptide for induction of WT1-specific Th1-type CD4+ T cells", MICROBIOL. IMMUNOL., vol. 52, 2008, pages 591 - 600, XP002590600 * |
GAO FG ET AL., CANCER RES., vol. 62, no. 22, 15 November 2002 (2002-11-15), pages 6438 - 41 |
INOUE K ET AL., BLOOD., vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2969 - 76 |
IWATA, M. ET AL., EUR. J. IMMUNOL, vol. 26, 1996, pages 2081 |
J. EXP. MED., vol. 184, 1996, pages 465 |
J. IMMUNOL., vol. 158, 1997, pages 1796 |
J. IMMUNOL., vol. 161, 1998, pages 5607 |
JOURNAL OF EXPERIMENTAL MEDICINE, vol. 190, 1999, pages 1669 |
KNIGHTS A.J. ET AL.: "Prediction of an HLA-DR-binding peptide derived from Wilms' tumor 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol", CANCER IMMUNOL. IMMUNOTHER., vol. 51, 2002, pages 271 - 281, XP002473128 * |
LEHE C. ET AL.: "The Wilms' Tumor antigen is a novel target for human CD4+ regulatory T cells : Implications for immunotherapy", CANCER RES., vol. 68, 2008, pages 6350 - 6359, XP055082460 * |
MAY R.J. ET AL.: "Peptide epitopes from the Wilms' Tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells", CLIN CANCER RES., vol. 13, no. 15, 2007, pages 4547 - 4555, XP002544528 * |
MENKE AL ET AL., INT REV CYTOL., vol. 181, 1998, pages 151 - 212 |
MULLER L. ET AL.: "Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells", HEMATOL.J., vol. 4, no. 1, 2003, pages 57 - 66, XP009044674 * |
OKA Y ET AL., IMMUNOGENETICS., vol. 51, no. 2, February 2000 (2000-02-01), pages 99 - 107 |
SCIENCE, vol. 274, 1996, pages 94 - 96 |
SCIENCE, vol. 279, 1998, pages 2103 - 2106 |
See also references of EP2626418A4 |
T. MANIATIS ET AL.: "Molecular Cloning", 1983, CSH LABORATORY |
TSUBOI A ET AL., LEUK RES., vol. 23, no. 5, May 1999 (1999-05-01), pages 499 - 505 |
YAMAGAMI T ET AL., BLOOD., vol. 87, no. 7, 1 April 1996 (1996-04-01), pages 2878 - 84 |
ZENG G, J IMMUNOTHER., vol. 24, no. 3, May 2001 (2001-05-01), pages 195 - 204 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11027003B2 (en) | 2003-11-05 | 2021-06-08 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US10124046B2 (en) | 2003-11-05 | 2018-11-13 | International Institute Of Cancer Immunology, Inc. | HLA-DR-binding antigen peptide derived from WT1 |
US11555814B2 (en) | 2007-02-27 | 2023-01-17 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper t cell and composition for use in the method |
US10139395B2 (en) | 2007-02-27 | 2018-11-27 | International Institute Of Cancer Immunology, Inc. | Method for activation of helper T cell and composition for use in the method |
JPWO2014042226A1 (ja) * | 2012-09-12 | 2016-08-18 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
US20160009781A1 (en) | 2012-09-12 | 2016-01-14 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper t-cell receptor genes |
JP2018143247A (ja) * | 2012-09-12 | 2018-09-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
US10815288B2 (en) | 2012-09-12 | 2020-10-27 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper T-cell receptor genes |
WO2014042226A1 (ja) * | 2012-09-12 | 2014-03-20 | 株式会社癌免疫研究所 | 抗原特異的ヘルパーt細胞レセプター遺伝子 |
RU2680588C2 (ru) * | 2012-09-12 | 2019-02-22 | Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк. | Гены рецепторов антигенспецифичных хелперных т-клеток |
US11091531B2 (en) | 2012-09-12 | 2021-08-17 | International Institute Of Cancer Immunology, Inc. | Antigen-specific helper T-cell receptor genes |
CN104797711A (zh) * | 2012-09-12 | 2015-07-22 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
CN104797711B (zh) * | 2012-09-12 | 2018-09-21 | 株式会社癌免疫研究所 | 抗原特异性辅助性t细胞受体基因 |
KR102158225B1 (ko) | 2012-12-17 | 2020-09-21 | 오츠카 세이야쿠 가부시키가이샤 | 헬퍼 t세포의 활성화 방법 |
CN110195040A (zh) * | 2012-12-17 | 2019-09-03 | 大塚制药株式会社 | 辅助性t细胞的活化方法 |
US9833493B2 (en) | 2012-12-17 | 2017-12-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
WO2014098012A1 (ja) * | 2012-12-17 | 2014-06-26 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
AU2013365067B2 (en) * | 2012-12-17 | 2017-10-05 | International Institute Of Cancer Immunology, Inc. | Method for activating helper T cell |
KR20150096697A (ko) * | 2012-12-17 | 2015-08-25 | 오츠카 세이야쿠 가부시키가이샤 | 헬퍼 t세포의 활성화 방법 |
JPWO2014098012A1 (ja) * | 2012-12-17 | 2017-01-12 | 大塚製薬株式会社 | ヘルパーt細胞の活性化方法 |
JP6005305B2 (ja) * | 2014-02-26 | 2016-10-12 | テラ株式会社 | Wt1抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
WO2015129790A1 (ja) * | 2014-02-26 | 2015-09-03 | 株式会社バイオイミュランス | Wt1抗原性ポリペプチド、及び該ポリペプチドを含む抗腫瘍剤 |
US10253075B2 (en) | 2014-02-26 | 2019-04-09 | tella, Inc. | WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide |
KR101804343B1 (ko) | 2014-02-26 | 2017-12-04 | 텔라 가부시키가이샤 | Wt1 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제 |
US10947503B2 (en) | 2014-12-25 | 2021-03-16 | International Institute Of Cancer Immunology, Inc. | Method for modifying T cell population |
WO2018088439A1 (ja) | 2016-11-09 | 2018-05-17 | 国立大学法人大阪大学 | T細胞集団の改変方法 |
US10899790B2 (en) | 2016-11-09 | 2021-01-26 | Osaka University | Method for modifying T cell population |
WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Wt1由来ペプチドのコンジュゲート体およびこれを含む組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6298101B2 (ja) | ヘルパーt細胞の活性化方法 | |
JP6530192B2 (ja) | ヘルパーt細胞の活性化方法 | |
TWI517859B (zh) | 癌抗原輔助肽 | |
KR101391561B1 (ko) | Hla-a*3303 구속성 wt1 펩티드, 및 그것을 포함하는 의약 조성물 | |
KR20090125067A (ko) | 헬퍼 t 세포의 활성화 방법 및 그를 위한 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180058552.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11830662 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012537718 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 225536 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2813557 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013500654 Country of ref document: PH Ref document number: MX/A/2013/003884 Country of ref document: MX Ref document number: 2011830662 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201305599 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201390509 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2011313327 Country of ref document: AU Date of ref document: 20111004 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20137011554 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15004047 Country of ref document: CO Ref document number: 13111246 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13877768 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013008230 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 245440 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 112013008230 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130404 |